

Raed Alhusayen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/721058/publications.pdf>

Version: 2024-02-01

39
papers

1,258
citations

516710

16
h-index

395702

33
g-index

41
all docs

41
docs citations

41
times ranked

1448
citing authors

#	ARTICLE	IF	CITATIONS
1	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90.	1.2	218
2	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 91-101.	1.2	206
3	Risk of Malignancy in Dermatomyositis and Polymyositis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 131-136.	1.2	143
4	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1092-1101.	1.2	77
5	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study. <i>Arthritis Care and Research</i> , 2019, 71, 1084-1091.	3.4	68
6	The critical role of macrophages in the pathogenesis of hidradenitis suppurativa. <i>Inflammation Research</i> , 2017, 66, 931-945.	4.0	51
7	Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 513-524.	1.2	39
8	Recent advances in managing and understanding pyoderma gangrenosum. <i>F1000Research</i> , 2019, 8, 2092.	1.6	38
9	Severe Physical Complications among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Drug Safety</i> , 2018, 41, 277-284.	3.2	34
10	Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1059-1062.	1.2	32
11	Improved keratinocyte carcinoma outcomes with annual dermatology assessment after solid organ transplantation: Population-based cohort study. <i>American Journal of Transplantation</i> , 2019, 19, 522-531.	4.7	30
12	Overview of Ultrasound Imaging Applications in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 521-529.	1.2	25
13	Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S42-S46.	1.2	24
14	Pharmacologic Interventions for Hidradenitis Suppurativa. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 283-291.	6.7	22
15	Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1302-1309.	1.2	21
16	Acitretin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 48-53.	1.2	19
17	Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 537-544.	1.2	18
18	Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. <i>International Journal of Dermatology</i> , 2021, 60, e140-e141.	1.0	18

#	ARTICLE	IF	CITATIONS
19	Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015. <i>Journal of Rheumatology</i> , 2020, 47, 1644-1651.	2.0	17
20	Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 484-487.	1.2	15
21	Association between Hidradenitis Suppurativa and Inflammatory Arthritis: A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2021, 237, 740-747.	2.1	15
22	Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. <i>International Journal of Dermatology</i> , 2021, 60, e459-e465.	1.0	14
23	Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1049-1051.	1.2	14
24	International collaboration and rapid harmonization across dermatologic COVID-19 registries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e261-e266.	1.2	13
25	Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2021, 73, 680-686.	3.4	12
26	Validating the diagnostic code for acne in a tertiary care dermatology centre. <i>European Journal of Dermatology</i> , 2015, 25, 469-471.	0.6	11
27	Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 604-612.	0.4	9
28	Hidradenitis suppurativa and Down syndrome: A systematic review and meta-analysis. <i>Pediatric Dermatology</i> , 2020, 37, 1044-1050.	0.9	9
29	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	1.6	9
30	Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 249-252.	1.2	8
31	Changes in the Practice Patterns and Demographics of Ontario Dermatologists. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 390-399.	1.2	6
32	Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e81-e82.	1.2	6
33	Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome. <i>Dermatology</i> , 2021, 237, 479-485.	2.1	5
34	Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. <i>Dermatologic Therapy</i> , 2021, 34, e14851.	1.7	3
35	Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study. <i>International Journal of Women's Dermatology</i> , 2021, 7, 346-348.	2.0	3
36	Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox. <i>British Journal of Dermatology</i> , 2022, 186, 768-769.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Common Dermatologic Disorders in Down Syndrome: Systematic Review. JMIR Dermatology, 2022, 5, e33391.	0.7	2
38	Provision of Dermatologic Care in a Universal Health Care System: A 17-Year Review. Journal of Cutaneous Medicine and Surgery, 2021, 25, 511-520.	1.2	1
39	Exploring Access to Surgical Interventions for Hidradenitis Suppurativa: Retrospective Population-Based Analysis. JMIR Dermatology, 2021, 4, e31047.	0.7	0